Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apollomics Inc. stock logo
APLM
Apollomics
$16.12
+0.8%
$16.99
$3.66
$42.12
$35.46M1.5310,725 shs889 shs
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$3.17
+0.5%
$2.40
$1.03
$8.48
$13.79M1.84.40 million shs39,940 shs
MAAQ
Mana Capital Acquisition
$1.88
+5.0%
$2.88
$5.35
$10.25
$15.28MN/A33,075 shs77,659 shs
SciSparc Ltd. stock logo
SPRC
SciSparc
$6.52
-5.6%
$4.81
$2.98
$80.10
$2.64M2.71360,237 shs7,800 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apollomics Inc. stock logo
APLM
Apollomics
-2.27%+21.99%+7.70%-18.62%+158.19%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-3.37%+3.62%-48.78%+154.03%+6.06%
MAAQ
Mana Capital Acquisition
0.00%+3.30%-7.84%+29.66%+339.87%
SciSparc Ltd. stock logo
SPRC
SciSparc
-12.64%-17.15%+95.20%+16.33%-90.86%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apollomics Inc. stock logo
APLM
Apollomics
$16.12
+0.8%
$16.99
$3.66
$42.12
$35.46M1.5310,725 shs889 shs
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$3.17
+0.5%
$2.40
$1.03
$8.48
$13.79M1.84.40 million shs39,940 shs
MAAQ
Mana Capital Acquisition
$1.88
+5.0%
$2.88
$5.35
$10.25
$15.28MN/A33,075 shs77,659 shs
SciSparc Ltd. stock logo
SPRC
SciSparc
$6.52
-5.6%
$4.81
$2.98
$80.10
$2.64M2.71360,237 shs7,800 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apollomics Inc. stock logo
APLM
Apollomics
-2.27%+21.99%+7.70%-18.62%+158.19%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-3.37%+3.62%-48.78%+154.03%+6.06%
MAAQ
Mana Capital Acquisition
0.00%+3.30%-7.84%+29.66%+339.87%
SciSparc Ltd. stock logo
SPRC
SciSparc
-12.64%-17.15%+95.20%+16.33%-90.86%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apollomics Inc. stock logo
APLM
Apollomics
1.00
SellN/AN/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
1.00
SellN/AN/A
MAAQ
Mana Capital Acquisition
0.00
N/AN/AN/A
SciSparc Ltd. stock logo
SPRC
SciSparc
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest SPRC, APLM, CYCN, and MAAQ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/29/2026
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
UpgradeSell (E+)Sell (D-)
3/27/2026
Apollomics Inc. stock logo
APLM
Apollomics
Reiterated RatingSell (D-)
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apollomics Inc. stock logo
APLM
Apollomics
$8.50M4.17N/AN/A($2.89) per share-5.58
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$2.07M6.62N/AN/A$2.31 per share1.37
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/AN/A
SciSparc Ltd. stock logo
SPRC
SciSparc
$860K3.03N/AN/A$12.93 per share0.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apollomics Inc. stock logo
APLM
Apollomics
-$10.94MN/AN/AN/AN/AN/AN/AN/AN/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-$3.53M-$1.16N/AN/AN/A-170.11%-39.23%-35.62%5/15/2026 (Estimated)
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/AN/AN/AN/AN/A
SciSparc Ltd. stock logo
SPRC
SciSparc
-$12.18MN/AN/AN/AN/AN/AN/AN/AN/A

Latest SPRC, APLM, CYCN, and MAAQ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/29/2026Q4 2025
SciSparc Ltd. stock logo
SPRC
SciSparc
N/A-$31.6050N/A-$31.6050N/A$0.20 million
3/30/2026Q4 2025
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-$0.38-$0.19+$0.19-$0.19$0.10 million$1.03 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Apollomics Inc. stock logo
APLM
Apollomics
N/AN/AN/AN/AN/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/AN/AN/AN/AN/A
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/A
SciSparc Ltd. stock logo
SPRC
SciSparc
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apollomics Inc. stock logo
APLM
Apollomics
N/A
0.96
0.96
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/A
5.15
5.15
MAAQ
Mana Capital Acquisition
N/AN/AN/A
SciSparc Ltd. stock logo
SPRC
SciSparc
N/A
2.41
2.38

Institutional Ownership

CompanyInstitutional Ownership
Apollomics Inc. stock logo
APLM
Apollomics
19.13%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
75.62%
MAAQ
Mana Capital Acquisition
68.44%
SciSparc Ltd. stock logo
SPRC
SciSparc
25.06%

Insider Ownership

CompanyInsider Ownership
Apollomics Inc. stock logo
APLM
Apollomics
N/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
34.30%
MAAQ
Mana Capital Acquisition
N/A
SciSparc Ltd. stock logo
SPRC
SciSparc
1.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apollomics Inc. stock logo
APLM
Apollomics
452.20 millionN/ANot Optionable
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
304.33 million2.85 millionNo Data
MAAQ
Mana Capital Acquisition
18.13 millionN/ANot Optionable
SciSparc Ltd. stock logo
SPRC
SciSparc
4400,000392,000Not Optionable

Recent News About These Companies

SciSparc (NASDAQ:SPRC) Shares Down 8.5% - What's Next?
Neurothera Labs Announces Continuance into Ontario
SciSparc Announces 1-for-9 Reverse Share Split

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apollomics stock logo

Apollomics NASDAQ:APLM

$16.12 +0.12 (+0.75%)
As of 12:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Cyclerion Therapeutics stock logo

Cyclerion Therapeutics NASDAQ:CYCN

$3.17 +0.02 (+0.51%)
As of 12:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Mana Capital Acquisition NASDAQ:MAAQ

$1.88 +0.09 (+5.03%)
As of 05/1/2026

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.

SciSparc stock logo

SciSparc NASDAQ:SPRC

$6.52 -0.39 (-5.63%)
As of 12:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.